Monomycolyl Glycerol Adjuvant for Th1 Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants for vaccines, particularly those requiring a Th1 response for pathogens like M. tuberculosis, are limited and often induce unsuitable immune responses, and there is a need for adjuvants that can effectively activate human dendritic cells to enhance immune responses.
Innovation Solution
The use of monomycolyl glycerol (MMG) and its synthetic homologues or modified versions as immunostimulatory lipids to activate human dendritic cells, promoting a strong Th1 response and long-lasting protective immunity, combined with delivery vehicles like cationic liposomes to enhance vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aluminum-based adjuvants (AlOH-salts) or MF-59 are used, then adjuvant effect is achieved, but Th2-biased response is induced which is unsuitable for TB vaccine requiring Th1 response
Solution Approach 1:
The patent changes the chemical composition parameters of the adjuvant from conventional aluminum-based salts or MF-59 to saponins (natural or synthetic), which fundamentally alters the immune response profile from Th2-biased to Th1-inducing, making it suitable for TB vaccination while maintaining adjuvant efficacy
Solution Approach 2:
The patent employs saponins, particularly quillaja saponins, which are naturally abundant, cost-effective, and can be produced in large quantities, providing an economical alternative to expensive proprietary adjuvants like MF-59 while achieving the desired Th1 immune response
2Object-affected harmful factors
If highly purified substances (recombinant proteins or peptides) are used as vaccines, then side-reactions are minimized, but immunogenicity is reduced and sufficient immune response is not induced
Solution Approach 1:
The patent introduces saponins as an intermediary substance that bridges the gap between highly purified antigens and the immune system. The saponins act as adjuvants that enhance the immunogenicity of purified recombinant proteins or peptides without introducing the side-reactions associated with less purified vaccine preparations
Solution Approach 2:
The patent creates a composite vaccine formulation combining highly purified antigenic substances (recombinant proteins or peptides) with saponin adjuvants. This composite approach maintains the purity benefits of recombinant antigens while adding the immune-stimulating properties of saponins to achieve sufficient protective immunity
3Reliability
If BCG vaccine is used, then protection against tuberculosis is provided, but satisfactory resistance is not achieved in every population and it does not always provide sufficient protection
Solution Approach 1:
The patent modifies the immunological parameters of TB vaccination by replacing BCG with recombinant antigen-based vaccines enhanced with saponin adjuvants. This changes the mechanism of protection from live attenuated bacteria to targeted antigen presentation with enhanced immunogenicity, achieving consistent Th1 response across different populations
Solution Approach 2:
The patent extracts and isolates specific protective antigens from Mycobacterium tuberculosis (such as ESAT-6, CFP-10, Ag85b) and uses them in recombinant vaccine formulations with saponin adjuvants, removing the need for live bacteria while retaining and enhancing the protective immune response
Data Source
AI summary
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.